E-nose Assess Immunotherapy Prognosis
January 21, 2020 | Terry Sharrer
Oncologists at the Netherlands Cancer Institute “hypothesized that molecular profiling of exhaled air may capture the inflammatory milieu related to the individual responsiveness to anti-programmed death ligand 1 (PD-1) therapy. This study aimed to determine the accuracy of exhaled breath analysis at baseline for assessing nonresponders versus responders to anti-PD-1 therapy in NSCLC patients.” The electronic nose had greater accuracy than the current method of immunohistochemistry. MORE
Image Credit: Pexels